Relapse and recurrence following a course of ECT: reasons for concern and strategies for further investigation.
Patients treated with electroconvulsive therapy (ECT) have a more severe illness. This severity is evidenced in the clinical profile of the illness, in the course of the illness, in the resistance to pharmacotherapy, and in the high relapse and recurrence rates after the course of ECT. In this article the authors explore some of the issues, particularly those of biological correlates of severe mood disorders and the continuation of treatment after ECT, which may be factors in this increased severity. The authors propose avenues for the investigation and treatment of severe mood disorders treated with ECT.
D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D003907:Dexamethasone; D004565:Electroconvulsive Therapy; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D009490:Neurosecretory Systems / Q000503:physiopathology; D017286:Polysomnography; D012008:Recurrence; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone
D000928:Antidepressive Agents; D013973:Thyrotropin-Releasing Hormone; D003907:Dexamethasone; D013972:Thyrotropin; D006854:Hydrocortisone